Abstract Background Hypoxia-inducible factor 2α (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of proteins involved with angiogenesis, proliferation, and metastasis. Casdatifan is a potent, selective, orally bioavailable HIF-2α inhibitor that has demonstrat...
R. McKay, J. Merchan, A. Patnaik et al.· The Oncologist· 0 citations
Abstract Background The randomized, double-blind, phase 3 LITESPARK-022 study (NCT05239728) showed significant disease-free survival benefit with the addition of belzutifan to adjuvant pembrolizumab in participants with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence following surgery. We presen...
T. Powles, T. Choueiri, J. Karam et al.· The Oncologist· 0 citations
Abstract Background For patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have relapsed after anti-programmed death protein 1 (anti–PD-1) or anti-programmed death ligand-1 (anti–PD-L1) treatment, second-line treatment options remain limited, consisting primarily of tyrosine kinase inhibit...
T. Choueiri, S. Pal, R. McKay et al.· The Oncologist· 0 citations
Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.
Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.